Drug profile · INN
hydroxycarbamide
HYDREA
hydroxycarbamide (HYDREA) is a ribonucleoside-diphosphate reductase rr1 inhibitor.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01XX05
Patents linked 0
Pipeline programs 8
News articles 0
Drug details — hydroxycarbamide
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 8
- Data quality
- 0.83
Quick answer
hydroxycarbamide (HYDREA) is a ribonucleoside-diphosphate reductase rr1 inhibitor.
Key facts
INN hydroxycarbamide
Brand HYDREA
Mechanism Ribonucleoside-diphosphate reductase RR1 inhibitor
Target Ribonucleoside-diphosphate reductase RR1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX05
Mechanism of action
Ribonucleoside-diphosphate reductase RR1 inhibitor
Primary target: Ribonucleoside-diphosphate reductase RR1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is hydroxycarbamide?
hydroxycarbamide (HYDREA) is a ribonucleoside-diphosphate reductase rr1 inhibitor.
What is the brand name for hydroxycarbamide?
HYDREA is a marketed brand name for hydroxycarbamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.